BECLOMETHASONE DIPROPIONATE MONOHYDRATE

US Previously Marketed

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C28H37ClO7.H2O
Molecular Weight	539.057
Optical Activity	UNSPECIFIED
Defined Stereocenters	8 / 8
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of BECLOMETHASONE DIPROPIONATE MONOHYDRATE

Structure Search

SMILES

O.CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C

InChI

InChIKey=QHQJZIXSVLFOHD-LYRZEVDOSA-N

InChI=1S/C28H37ClO7.H2O/c1-6-23(33)35-15-22(32)28(36-24(34)7-2)16(3)12-20-19-9-8-17-13-18(30)10-11-25(17,4)27(19,29)21(31)14-26(20,28)5;/h10-11,13,16,19-21,31H,6-9,12,14-15H2,1-5H3;1H2/t16-,19-,20-,21-,25-,26-,27-,28-;/m0./s1

HIDE SMILES / InChI

Molecular Formula	H2O
Molecular Weight	18.0153
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C28H37ClO7
Molecular Weight	521.042
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	8 / 8
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020911s025lbl.pdf
Curator's Comment: description was created based on several sources, including http://reference.medscape.com/drug/qvar-beclomethasone-inhaled-343427

Beclometasone dipropionate or beclomethasone dipropionate is sold under the brand name Qvar among others. Beclomethasone dipropionate is a corticosteroid demonstrating potent anti-inflammatory activity. The precise mechanism of corticosteroid action on asthma is not known. Corticosteroids have been shown to have multiple anti-inflammatory effects, inhibiting both inflammatory cells (e.g., mast cells, eosinophils, basophils, lymphocytes, macrophages, and neutrophils) and release of inflammatory mediators (e.g., histamine, eicosanoids, leukotrienes, and cytokines). These anti-inflammatory actions of corticosteroids may contribute to their efficacy in asthma. Beclomethasone dipropionate is a prodrug that is rapidly activated by hydrolysis to the active monoester, 17 monopropionate (17-BMP). Beclomethasone 17 monopropionate has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor, which is approximately 13 times that of dexamethasone, 6 times that of triamcinolone acetonide, 1.5 times that of budesonide and 25 times that of beclomethasone dipropionate. The clinical significance of these findings is unknown. Studies in patients with asthma have shown a favorable ratio between topical anti-inflammatory activity and systemic corticosteroid effects with recommended doses of QVAR. Beclometasone dipropionate was first patented in 1962 and used medically in 1972. Common side effects with the inhaled form include respiratory infections, headaches, and throat inflammation. Serious side effects include an increased risk of infection, cataracts, Cushing’s syndrome, and severe allergic reactions. Long term use of the pill form may cause adrenal insufficiency. The pills may also cause mood or personality changes. The inhaled form is generally regarded as safe in pregnancy. Beclometasone is mainly a glucocorticoid.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Glucocorticoid receptor 173 Target ID: CHEMBL2034 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16507850	Agonist 2752

Conditions

Condition	Modality	Targets	Highest Phase	Product
Asthma 244 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020911s025lbl.pdf	Palliative		Approved 8583	QVAR® 40 Approved Use QVAR is indicated in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. QVAR is also indicated for asthma patients who require systemic corticosteroid administration, where adding QVAR may reduce or eliminate the need for the systemic corticosteroids. Launch Date 2000

C_max

Value	Dose	Analyte	Population
3103.4 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28937845	160 μg single, respiratory dose: 160 μg route of administration: Respiratory experiment type: SINGLE co-administered:	BECLOMETHASONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
6635.1 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28937845	320 μg single, respiratory dose: 320 μg route of administration: Respiratory experiment type: SINGLE co-administered:	BECLOMETHASONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
88 pg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020911s029s030lbl.pdf	320 μg single, respiratory dose: 320 μg route of administration: Respiratory experiment type: SINGLE co-administered:	BECLOMETHASONE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
181.95 pg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf	320 μg single, nasal dose: 320 μg route of administration: Nasal experiment type: SINGLE co-administered:	BECLOMETHASONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
262.65 pg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf	320 μg single, nasal dose: 320 μg route of administration: Nasal experiment type: SINGLE co-administered:	BECLOMETHASONE 17-MONOPROPIONATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
283.5 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28937845	160 μg single, respiratory dose: 160 μg route of administration: Respiratory experiment type: SINGLE co-administered:	BECLOMETHASONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
623.6 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28937845	320 μg single, respiratory dose: 320 μg route of administration: Respiratory experiment type: SINGLE co-administered:	BECLOMETHASONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
88.23 pg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf	320 μg single, nasal dose: 320 μg route of administration: Nasal experiment type: SINGLE co-administered:	BECLOMETHASONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
1661.53 pg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf	320 μg single, nasal dose: 320 μg route of administration: Nasal experiment type: SINGLE co-administered:	BECLOMETHASONE 17-MONOPROPIONATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
0.57 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28937845	160 μg single, respiratory dose: 160 μg route of administration: Respiratory experiment type: SINGLE co-administered:	BECLOMETHASONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
0.92 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28937845	320 μg single, respiratory dose: 320 μg route of administration: Respiratory experiment type: SINGLE co-administered:	BECLOMETHASONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
0.278 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf	320 μg single, nasal dose: 320 μg route of administration: Nasal experiment type: SINGLE co-administered:	BECLOMETHASONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
4.457 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf	320 μg single, nasal dose: 320 μg route of administration: Nasal experiment type: SINGLE co-administered:	BECLOMETHASONE 17-MONOPROPIONATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
13% OTHER GOV https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Beconase_AQ/pdf/BECONASE-PI-PIL.PDF			BECLOMETHASONE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
320 ug single, respiratory Highest studied dose Dose: 320 ug Route: respiratory Route: single Dose: 320 ug Sources: https://pubmed.ncbi.nlm.nih.gov/28937845/	healthy, 18 - 45 years Health Status: healthy Age Group: 18 - 45 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/28937845/	Disc. AE: Presyncope... Other AEs: Headache, Nausea... AEs leading to discontinuation/dose reduction: Presyncope (1 patient) Other AEs: Headache (2 patients) Nausea (1 patient) Tonsillar hypertrophy (1 patient) Cerumen impaction (1 patient) Oropharyngeal pain (1 patient) Anxiety (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/28937845/
40 ug 2 times / day steady, respiratory Recommended Dose: 40 ug, 2 times / day Route: respiratory Route: steady Dose: 40 ug, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21324520/	unhealthy, 5-18 years Health Status: unhealthy Age Group: 5-18 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/21324520/	Sources: https://pubmed.ncbi.nlm.nih.gov/21324520/
40 ug 2 times / day steady, respiratory Recommended Dose: 40 ug, 2 times / day Route: respiratory Route: steady Dose: 40 ug, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21324520/	unhealthy, 5-18 years Health Status: unhealthy Age Group: 5-18 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/21324520/	Sources: https://pubmed.ncbi.nlm.nih.gov/21324520/
320 ug 2 times / day steady, respiratory Highest studied dose Dose: 320 ug, 2 times / day Route: respiratory Route: steady Dose: 320 ug, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020911s029s030lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020911s029s030lbl.pdf	Other AEs: Headache, Pain... Other AEs: Headache (25%) Pain (5%) Back pain (4%) Dysphonia (4%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020911s029s030lbl.pdf
320 ug 1 times / day steady, respiratory Dose: 320 ug, 1 times / day Route: respiratory Route: steady Dose: 320 ug, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26653155/	unhealthy, adults and children Health Status: unhealthy Age Group: adults and children Sex: unknown Sources: https://pubmed.ncbi.nlm.nih.gov/26653155/	Disc. AE: Nasal mucosal disorder NOS... AEs leading to discontinuation/dose reduction: Nasal mucosal disorder NOS (17 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/26653155/
80 ug 1 times / day steady, respiratory Dose: 80 ug, 1 times / day Route: respiratory Route: steady Dose: 80 ug, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT01697956	unhealthy, child Health Status: unhealthy Age Group: child Sources: https://clinicaltrials.gov/ct2/show/NCT01697956	Other AEs: Epistaxis, Pyrexia... Other AEs: Epistaxis (below serious, 5 patients) Pyrexia (below serious, 5 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT01697956
80 ug 1 times / day steady, respiratory Dose: 80 ug, 1 times / day Route: respiratory Route: steady Dose: 80 ug, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT01783548	unhealthy, child Health Status: unhealthy Age Group: child Sources: https://clinicaltrials.gov/ct2/show/NCT01783548	Other AEs: Epistaxis... Other AEs: Epistaxis (below serious, 18 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT01783548

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946 inducer 1087	inducer 440

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
BCRP 910 OATP1B1 1079 OATP1B3 961	CYP3A5 446 CYP3A7 109 esterase 74 P-gp 2052	UGT2B10 2 UGT2B17 2 CYP1A2 832 UGT1A 2 P-gp 301 MRP1 74 MRP2 146

Drug as perpetrator

Target	Modality	Activity
OATP1B3 970	inhibitor 4027 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2864424/	yes [IC50 1.4 uM]
OATP1B1 1095	inhibitor 4027 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2864424/	yes [IC50 6.7 uM]
BCRP 985	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/15365089/	yes [Inhibition 40.4 uM]
CYP1A2 2333	inducer 1966 Sources: https://iubmb.onlinelibrary.wiley.com/doi/abs/10.1080/10258140412331286946 Page: 3.0	yes
CYP2C9 2497	inducer 1966 Sources: https://iubmb.onlinelibrary.wiley.com/doi/abs/10.1080/10258140412331286946 Page: 3.0	yes
CYP3A4 2633	inducer 1966 Sources: https://iubmb.onlinelibrary.wiley.com/doi/abs/10.1080/10258140412331286946 Page: 3.0	yes
MRP1 232	inducer 1966 Sources: https://iubmb.onlinelibrary.wiley.com/doi/abs/10.1080/10258140412331286946 Page: 3.0	yes
MRP2 625	inducer 1966 Sources: https://iubmb.onlinelibrary.wiley.com/doi/abs/10.1080/10258140412331286946 Page: 3.0	yes
P-gp 1932	inducer 1966 Sources: https://iubmb.onlinelibrary.wiley.com/doi/abs/10.1080/10258140412331286946 Page: 3.0	yes
UGT1A 6	inducer 1966 Sources: https://iubmb.onlinelibrary.wiley.com/doi/abs/10.1080/10258140412331286946 Page: 3.0	yes
UGT2B10 33	inducer 1966 Sources: https://iubmb.onlinelibrary.wiley.com/doi/abs/10.1080/10258140412331286946 Page: 3.0	yes
UGT2B17 33	inducer 1966 Sources: https://iubmb.onlinelibrary.wiley.com/doi/abs/10.1080/10258140412331286946 Page: 3.0	yes

Drug as victim

Target	Modality	Activity
CYP3A7 109	substrate 4014 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3629798/	no
CYP3A4 1946	substrate 4014 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3629798/	yes
CYP3A5 446	substrate 4014 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3629798/	yes
P-gp 2052	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/22464980/ Page: 6.0	yes
esterase 74	substrate 4014 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3629798/	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:3001	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:3001
ChemicalBook	CB7694093	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7694093
eMolecules	31224812	https://www.emolecules.com/cgi-bin/more?vid=31224812
MolPort	MolPort-003-844-701	https://www.molport.com/shop/molecule-link/MolPort-003-844-701
ZINC	ZINC000004097285	http://zinc15.docking.org/substances/ZINC000004097285

PubMed

Title	Date	PubMed
On the inappropriateness of an EM algorithm based procedure for blinded sample size re-estimation.	2002-01-30	11782057
Inhaled steroids for children's acute asthma exacerbations?	2002-01	11814283
Duration of steroid therapy determines dose-response effect.	2002-01	11796477
Initial improvements in lung function and bronchial hyperresponsiveness are maintained during 5 years of treatment with inhaled beclomethasone dipropionate and terbutaline.	2002-01	11796444
Evaluation of an asthma management program for Chinese children with mild-to-moderate asthma in Hong Kong.	2002-01	11747256
Growth factors in idiopathic pulmonary fibrosis: relative roles.	2002	11806848
Autocrine regulation of asthmatic airway inflammation: role of airway smooth muscle.	2002	11806846
Cost analysis of the use of inhaled corticosteroids in the treatment of asthma: a 1-year follow-up.	2001-12	11778798
Effects of theophylline withdrawal in well-controlled asthmatics treated with inhaled corticosteroid.	2001-12	11758890
Inhaled beclomethasone dipropionate improves acoustic measures of voice in patients with asthma.	2001-12	11742909
Electro-hydrodynamic atomization of drug solutions for inhalation purposes.	2001-12	11717241
Beclomethasone, budesonide and fluticasone propionate inhibit human neutrophil apoptosis.	2001-11-23	11730731
Apoptosis of airway epithelial cells induced by corticosteroids.	2001-11-15	11734450
[Difficulties in diagnosis and treatment of asthma in the elderly].	2001-11	11774711
Effect of salmeterol and salmeterol plus beclomethasone on saliva flow and IgA in patients with moderate-persistent chronic asthma.	2001-11	11730186
Effects of inhaled corticosteroid and short courses of oral corticosteroids on bone mineral density in asthmatic patients : a 4-year longitudinal study.	2001-11	11713121
Decreased osteocalcin levels in patients with chronic obstructive pulmonary disease using long-term inhaled beclomethasone dipropionate.	2001-11	11699053
Effects of 2 inhaled corticosteroids on growth: results of a randomized controlled trial.	2001-11	11695935
Chronic asthma.	2001-10-27	11679388
Evaluation of quality of life in children and teenagers with allergic rhinitis: adaptation and validation of the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ).	2001-10-25	11674923
Systematic review of clinical effectiveness of pressurised metered dose inhalers versus other hand held inhaler devices for delivering corticosteroids in asthma.	2001-10-20	11668133
Asthma stability after oral prednisone: a clinical model for comparing inhaled steroid potency.	2001-10-01	11673199
[Inhaled corticosteroid therapy in childhood asthma].	2001-10	11676147
[Recent advance in inhaled corticosteroid therapy].	2001-10	11676146
[Inhaled corticosteroids: first-line therapy in asthma].	2001-10	11676140
What's new: newly approved drugs for children.	2001-10	11581490
Beclomethasone diproprionate reduced airway inflammation without adrenal suppression in young children with cystic fibrosis: a pilot study.	2001-10	11568990
Symptomatic adrenal insufficiency during inhaled corticosteroid treatment.	2001-10	11567945
Exhaled nitric oxide and hydrogen peroxide in patients with chronic obstructive pulmonary disease: effects of inhaled beclomethasone.	2001-09-15	11587988
Long-acting inhaled beta(2)-agonist therapy in asthma.	2001-09-15	11587972
Treatment update: nonallergic rhinitis.	2001-09-13	11552668
Improved safety with equivalent asthma control in adults with chronic severe asthma on high-dose fluticasone propionate.	2001-09	11555383
Effect of seasonal allergen exposure on mucosal IL-16 and CD4+ cells in patients with allergic rhinitis.	2001-09	11551252
Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis.	2001-08-04	11485952
Effects of withdrawal of inhaled steroids in men with severe irreversible airflow obstruction.	2001-08-01	11500334
The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics.	2001-08	11529281
Effects of pranlukast, a cysteinyl leukotriene receptor 1 antagonist, combined with inhaled beclomethasone in patients with moderate or severe asthma.	2001-08	11527250
Antibacterial activity of apical surface fluid from the human airway cell line Calu-3: pharmacologic alteration by corticosteroids and beta(2)-agonists.	2001-08	11509329
Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).	2001-08	11483846
[Tracheobronchopathia osteochondroplastica].	2001-07	11802998
Improved asthma control after changing from low-to-medium doses of other inhaled corticosteroids to low-dose fluticasone propionate.	2001-06-08	11549975
A comparison of clinical use of fluticasone propionate and beclomethasone dipropionate in pediatric asthma.	2001-06	11559968
[Effect of FP inhalation and airway inflammation assessed by ECP in asthma].	2001-06	11530386
Influence of respiratory spacer devices on aerodynamic particle size distribution and fine particle mass of beclomethasone from metered-dose inhalers.	2001	11791688
Oral montelukast versus inhaled beclomethasone in 6- to 11-year-old children with asthma: results of an open-label extension study evaluating long-term safety, satisfaction, and adherence with therapy.	2001	11759189
Small airway inflammation in asthma.	2001	11737932
Comparison of hydrofluoroalkane-beclomethasone dipropionate Autohaler with budesonide Turbuhaler in asthma control.	2001	11694816
Oral steroids for bronchiectasis (stable and acute exacerbations).	2001	11687146
Aerosol characterization of nebulized intranasal glucocorticoid formulations.	2001	11681655
Comparison of beclomethasone dipropionate delivery by easyhaler dry powder inhaler and pMDI plus large volume spacer.	2001	11681653

Patents

Sample Use Guides

In Vivo Use Guide

Administer QVAR (beclomethasone dipropionate HFA 40 ug) by the orally inhaled route only. Patients should prime QVAR by actuating into the air twice before using for the first time or if QVAR has not been used for over 10 days.

Route of Administration: Other

In Vitro Use Guide

Incubation of challenged rings (bronchial rings from nonatopic humans) for 3 h with 3 x 10(-6) M beclomethasone dipropionate (BDP) restored the relaxant effect, suggesting reversal of beta(2)-AR pathway dysfunction.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:13:17 GMT 2025` Edited by `admin` on `Mon Mar 31 18:13:17 GMT 2025`
Record UNII	4H7L9AI22I
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BECLOMETASONE DIPROPIONATE MONOHYDRATE

Preferred Name

English

BECLOMETHASONE DIPROPIONATE MONOHYDRATE

Common Name

English

BECLOMETASONE DIPROPIONATE MONOHYDRATE [EP IMPURITY]

Common Name

English

BECLOMETASONE DIPROPIONATE MONOHYDRATE [EP MONOGRAPH]

Common Name

English

Beclometasone dipropionate monohydrate [WHO-DD]

Common Name

English

BECLOMETHASONE DIPROPIONATE MONOHYDRATE [ORANGE BOOK]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C521